ABSTRACT
Background In Alzheimer’s disease, plasma Aβ1-42 and p-tau predict high amyloid status from Aβ-PET, however the extent to which combination of both plasma assays predict remains unknown.
Methods Prototype Simoa assays were used to measure plasma samples from cognitively normal (CN) and symptomatic adults in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Results The p-tau181/Aβ1-42 ratio showed the best prediction of Aβ-PET across all participants (AUC=0.905, 95%CI:0.86-0.95) and in CN (AUC=0.873; 0.80–0.94), and symptomatic (AUC=0.908; 0.82–1.00) adults. Plasma p-tau181/Aβ1-42 ratio correlated with CSF-p-tau181 (Elecsys®, Spearman’s ρ=0.74, P<0.0001) and predicted abnormal CSF Aβ (AUC=0.816, 0.74-0.89). The p-tau181/Aβ1-42 ratio also predicted future rates of cognitive decline assessed by AIBL PACC or CDR-SOB (P<0.0001).
Discussion Plasma p-tau181/Aβ1-42 ratio predicted both Aβ-PET status and cognitive decline, demonstrating potential as both a diagnostic aid and as a screening and prognostic assay for preclinical Alzheimer’s disease trials.
Competing Interest Statement
Eugeen Vanmechelen is cofounder and shareholder of ADx NeuroSciences. Erik Stoops is employee and shareholder of ADx NeuroSciences. Jeroen Vanbrabant, Nele Dewit and Kimberley Mauroo are employees of ADx NeuroSciences. Paul Maruff is a full-time employee of Cogstate Ltd. Christopher C. Rowe has received research grants from NHMRC, Enigma Australia, Biogen, Eisai and Abbvie; he is on the scientific advisory board for Cerveau Technologies and consulted for Prothena, Eisai, Roche and Biogen Australia. The other authors did not report any conflict of interest.
Funding Statement
This work was supported through AIBL and ADx Neurosciences
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of St Vincents Health and Hollywood Private Hospital gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations of interest: Eugeen Vanmechelen is cofounder and shareholder of ADx NeuroSciences. Erik Stoops is employee and shareholder of ADx NeuroSciences. Jeroen Vanbrabant, Nele Dewit and Kimberley Mauroo are employees of ADx NeuroSciences. Paul Maruff is a full-time employee of Cogstate Ltd. Christopher C. Rowe has received research grants from NHMRC, Enigma Australia, Biogen, Eisai and Abbvie; he is on the scientific advisory board for Cerveau Technologies and consulted for Prothena, Eisai, Roche and Biogen Australia. The other authors did not report any conflict of interest.
Funding sources: This work was supported through AIBL and ADx Neurosciences
Data Availability
Most data produced in the present study are available upon reasonable request to the authors
